# PRODUCT INFORMATION



# PD 173955

Item No. 30618

CAS Registry No.: 260415-63-2

Formal Name: 6-(2,6-dichlorophenyl)-8-methyl-

2-[[3-(methylthio)phenyl]amino]-

pyrido[2,3-d]pyrimidin-7(8H)-one


MF:  $C_{21}H_{16}CI_2N_4OS$ 

FW: 443.4 **Purity:** ≥98%

 $\lambda_{max}$ : 210, 255, 361 nm UV/Vis.: Supplied as: A crystalline solid

Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



#### **Laboratory Procedures**

PD 173955 is supplied as a crystalline solid. A stock solution may be made by dissolving the PD 173955 in the solvent of choice, which should be purged with an inert gas. PD 173955 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of PD 173955 in these solvents is approximately 1 mg/ml.

#### Description

PD 173955 is a tyrosine kinase inhibitor. <sup>1,2</sup> It inhibits c-Src, Yes, and LCK ( $IC_{50}$ s = 25, 22, and 5 nM, respectively), as well as Bcr-Abl and c-Kit (IC<sub>50</sub>s = 1-2 and 25 nM, respectively), and is selective for these kinases over the insulin receptor (InsR), α-FGFR, basic FGFR (bFGFR), PDGFR, and PKC.<sup>1-3</sup> PD 173955 (5,000 nM) induces cell cycle arrest at the G<sub>2</sub>/M phase in DU145 prostate, SKOV3 ovarian, HT-29 colon, A549 lung, and A431 skin cancer cells. 1 It inhibits proliferation of MDA-MB-468 and MCF-7 breast cancer cells (IC50s = 500 and 1,000 nM, respectively), as well as patient-derived peripheral blood chronic myelogenous leukemia (CML) progenitor cells (IC<sub>50</sub>= ~7.5 nM).<sup>1,2</sup>

## References

- 1. Moasser, M.M., Srethapakdi, M., Sachar, K.S., et al. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. 59(24), 145-152 (1999).
- Wisniewski, D., Lambek, C.L., Liu, C., et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res. 62(15), 4244-4255 (2002).
- Kraker, A.J., Hartl, B.G., Amar, A.M., et al. Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem. Pharmacol. 60(7), 885-898 (2000).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

## WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 01/04/2023

## **CAYMAN CHEMICAL**

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM